

GLOBAL DEVELOPED EQUITY ALLOCATION FUND

Quarterly Investment Review

PRODUCT OVERVIEW

The GMO Global Developed Equity Allocation Fund seeks to generate total return greater than that of the MSCI World Index.

The philosophy that underlies all of GMO's Asset Allocation investment strategies is the belief that, at times and in the short term, the pricing of asset classes can deviate from true intrinsic value but mean reverts to appropriate valuation levels over a complete market cycle. Using GMO's 7-Year Asset Class Forecasts, the Fund seeks to allocate to areas of the global equity markets we believe are most attractively valued. Our approach combines the best of GMO's top-down Asset Allocation views and bottom-up equity research to identify mispricings at both the asset class and individual security levels. The Fund allocates to equity strategies that are actively managed by other GMO investment teams with expertise and experience in security selection within their respective markets. The Fund is allowed to invest up to 10% (at time of purchase) in emerging market equities.

MAJOR PERFORMANCE DRIVERS

- Top-down asset allocation was negative. The headline positions of emphasizing Developed ex-U.S. over U.S. equities, along with emphasizing value equities over growth equities, both worked poorly for the quarter.
- Security selection was positive for the quarter, with good outcomes in Developed ex-U.S., emerging markets, Japan Fundamental Value and Resource exposures.

U.S. equities accounted for 51.9% of the total portfolio on average through the quarter, comprised of 2.1% in Domestic Resilience, 2.9% in U.S. Small Cap Value, 4.1% in U.S. Small Cap Quality, 12.3% in broad U.S., 14.6% in U.S. Opportunistic Value, and the remainder in the Quality and Resource equity strategies. This leaves the portfolio 20.0% underweight U.S. equities in total, which had a negative impact on relative performance as the MSCI USA Index returned 15.2%, ahead of the MSCI World return of 13.8%. Security selection in the U.S. was difficult as, in aggregate, our U.S. portfolio returned 12.3%. An overweight position in Lam Research (Information Technology) featured in the top five biggest individual contributors to relative performance for the quarter, while underweight positions in Micron Technology (Information Technology), Advanced Micro Devices (Information Technology), and Intel (Information Technology) featured among the five largest individual detractors.

Developed ex-U.S. equities accounted for an average weight of 44.8% of the portfolio for the quarter, including 6.0% in Japan Fundamental Value, 10.9% in International Opportunistic Value, 26.6% in Developed ex-U.S., along with some exposure from the Quality and Resource equity strategies. This overweight position in Developed ex-U.S. had a negative impact on relative performance as the MSCI World ex-USA Index returned 10.2%, trailing MSCI World. Security selection within developed markets was strong, as the portfolio returned 12.6% in aggregate. Overweight positions in Panasonic Holdings (Japan Consumer Discretionary), Nokia (Finland Information Technology), Murata Manufacturing (Japan Information Technology), and STMicroelectronics (France Information Technology) featured in the top five biggest individual contributors to relative performance for the quarter, while overweight positions in Inpex (Japan Energy) and Mitsui & Co (Japan Industrials) were among the largest individual detractors.

The exposure to Emerging Market equities has reduced considerably and represented 3.5% of the total portfolio weight on average during the quarter. This represents an overweight in Emerging Market equities, which had a positive impact on relative performance as the MSCI Emerging Markets Index returned 24.1%, ahead of the MSCI World return of 13.8%. Security selection was solid, as the portfolio returned 26.7% in aggregate. No Emerging Market names featured in the top five biggest individual contributors to, or detractors from, relative performance at the total portfolio level.

Portfolio weights, as a percent of equity, for the positions mentioned were: Lam Research (1.0%), Micron Technology (0.0%), Advanced Micro Devices (0.0%), Intel (0.0%), Panasonic Holdings (0.9%), Nokia (0.8%), Murata Manufacturing (0.4%), STMicroelectronics (0.4%), Inpex (0.5%) and Mitsui & Co (0.6%).

GLOBAL DEVELOPED EQUITY ALLOCATION FUND

Quarterly Investment Review

ANNUALIZED RETURNS (USD, %) (QUARTER-END)

	Quarter-End	YTD	1-Year	3-Year	5-Year	10-Year	Since Inception
Global Developed Equity Allocation Fund (net)	11.69	15.15	31.96	21.17	12.13	12.72	8.84
Global Developed Equity Allocation Fund (gross)	11.83	15.45	32.66	21.81	12.72	13.31	9.40
MSCI World	13.76	9.69	21.34	19.24	11.47	13.14	9.02
Value Add	-2.07	+5.46	+10.63	+1.93	+0.66	-0.42	-0.19

Net of all fees and expenses after reimbursement by the Manager, but not transaction costs, if any. If certain expenses were not reimbursed, performance would be lower. Gross of fees, expenses and transaction costs, if any. If these fees, expenses and costs were included, performance would be lower. **Performance data quoted represents past performance and is not indicative of future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance data may be lower or higher than the performance data provided herein. To obtain performance information to the most recent month-end, visit www.gmo.com.** Returns include a substantial, one-time litigation settlement recovery received on December 16, 2024. This event contributed 1.42% to 2024 annual performance. Performance for other periods, including this date, was also positively impacted, sometimes materially. Without this recovery, performance would have been lower in both absolute terms and relative to the benchmark. Returns reflect a significant, one-time increase to the net assets on November 26, 2025 attributable to European Union discriminatory tax refunds. These refunds contributed 1.25% to 2025 annual performance. Returns for other periods that include the date/period mentioned above were also positively impacted, sometimes substantially. In the absence of the refunds, performance would have been lower, both in absolute terms and relative to the benchmark. Returns include a substantial, one-time proceed from the sale of certain Russian securities. The one-time sale of these securities contributed 0.20% (1-day performance impact). Performance for other time periods was also positively impacted. Without these proceeds, performance would have been lower. Additional information is available upon request.

Inception Date: 16-Jun-05

Performance for the year of inception is less than a full calendar year. Returns shown for periods greater than one year are on an annualized basis.

Risks: Risks associated with investing in the Fund may include: (1) Market Risk - Equities: the market price of equities may decline due to factors affecting the issuer, its industries, or the economy and equity markets generally. Declines in stock market prices generally are likely to reduce the net asset value of the Fund's shares; (2) Management and Operational Risk: the risk that GMO's investment techniques will fail to produce desired results, including annualized returns and annualized volatility; and (3) Non-U.S. Investment Risk: the market prices of many non-U.S. securities (particularly of companies tied economically to emerging countries) fluctuate more than those of U.S. securities. Many non-U.S. markets (particularly emerging markets) are less stable, smaller, less liquid, and less regulated than U.S. markets, and the cost of trading in those markets often is higher than it is in U.S. markets. For a more complete discussion of these and other risks, please consult the Fund's Prospectus. **Performance Returns:** Annualized Returns may include the impact of purchase premiums and redemption fees. The GMO Trust funds are distributed in the United States by Funds Distributor LLC. GMO and Funds Distributor LLC are not affiliated.

Net Expense Ratio: 0.54%; Gross Expense Ratio: 0.62% Net Expense Ratio reflects the reduction of expenses from fee reimbursements. The fee reimbursements will continue until at least 30 June 2027. Elimination of this reimbursement will result in higher fees and lower performance. Gross Expense Ratio is equal to the Funds Total Annual Operating Expenses set forth in the Funds most recent prospectus dated 30 June 2026.

IMPORTANT INFORMATION

An investor should consider the fund's investment objectives, risks, charges and expenses before investing. This and other important information can be found in the funds prospectus. To obtain a prospectus please visit www.gmo.com. Read the prospectus carefully before investing.

Benchmark(s): The MSCI World Index (MSCI Standard Index Series, net of withholding tax) is an independently maintained and widely published index comprised of global developed markets. MSCI data may not be reproduced or used for any other purpose. MSCI provides no warranties, has not prepared or approved this report, and has no liability hereunder.

The GMO Trust funds are distributed in the United States by Funds Distributor LLC. GMO and Funds Distributor LLC are not affiliated.

ABOUT GMO

Founded in 1977, GMO is a global asset manager committed to delivering superior performance and advice to our clients. We are privately owned, which allows us to singularly focus on our sole business – achieving outstanding long-term client investment outcomes. Offering multi-asset, equity, fixed income, and alternative strategies, we invest with a long-term, valuation-based philosophical approach.

AMSTERDAM

BOSTON

LONDON

SAN FRANCISCO*

SINGAPORE

SYDNEY

TOKYO**

*GMO's West Coast Hub is comprised of members of Investment, Global Client Relations, and other teams located in and around the Greater San Francisco area

**Representative Office

www.GMO.com